Table 1.
Baseline characteristics by standard and intensive glycemic control treatment groups for the subjects available for analyses of worsening ACR and eGFR
| Standard |
Intensive |
P |
|
|---|---|---|---|
| ACR subjects | |||
| A1C, % (mmol/mol) | 9.37 ± 1.48 (700) (79 ± 16.2) | 9.38 ± 1.44 (686) (79 ± 15.7) | <0.0001 |
| SBP, sitting, mmHg | 130.80 ± 16.41 (697) | 131.20 ± 15.64 (683) | <0.0001 |
| DBP, sitting, mmHg | 76.05 ± 10.11 (697) | 75.64 ± 10.05 (683) | <0.0001 |
| PP, mmHg | 54.77 ± 13.23 (697) | 54.46 ± 13.22 (683) | <0.0001 |
| No albuminuria (n) | 461 | 437 | |
| Microalbuminuria (n) | 239 | 249 | |
| ACEI or ARB (n/n) | 465/48 | 482/43 | |
| eGFR subjects | |||
| A1C, % (mmol/mol) | 9.42 ± 1.54 (842) (79 ± 16.8) | 9.38 ± 1.46 (826) (79 ± 16.0) | <0.0001 |
| SBP, sitting, mmHg | 131.70 ± 16.81 (837) | 131.20 ± 16.22 (824) | <0.0001 |
| DBP, sitting, mmHg | 76.09 ± 10.23 (837) | 75.81 ± 10.13 (824) | <0.0001 |
| PP, mmHg | 55.62 ± 13.81 (838) | 55.38 ± 13.83 (823) | <0.0001 |
| Stage 1 CKD (n) | 345 | 348 | |
| Stage 2 CKD (n) | 418 | 400 | |
| Stage 3 CKD (n) | 80 | 79 | |
| ACEI or ARB (n/n) | 577/51 | 547/59 |
Data are means ± SD (n) unless otherwise indicated.